Partners Capital Investment Group LLP Takes $170,000 Position in Urogen Pharma $URGN

Key Points

• Partners Capital Investment Group LLP has invested $170,000 in Urogen Pharma by acquiring 15,384 shares during the first quarter.
• Urogen Pharma's stock opened at $19.78 and has a market cap of $915.10 million, while the company reported a negative EPS of ($1.05) for the last quarter, missing estimates.
• Analysts have mixed opinions on Urogen Pharma, with a consensus rating of "Buy" and an average price target of $32.00.

Partners Capital Investment Group LLP bought a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 15,384 shares of the company's stock, valued at approximately $170,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of Urogen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after buying an additional 5,140 shares during the period. Lazard Asset Management LLC bought a new position in shares of Urogen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC grew its stake in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma during the 4th quarter valued at $101,000. Finally, ProShare Advisors LLC bought a new stake in Urogen Pharma in the fourth quarter worth $137,000. 91.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company's stock, valued at $2,622,171.01. This represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel owned 41,492 shares in the company, valued at $794,156.88. This trade represents a 15.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,833 shares of company stock worth $457,467. 4.70% of the stock is owned by insiders.

Urogen Pharma Stock Performance

Shares of URGN stock traded down $0.01 on Wednesday, hitting $19.50. The company's stock had a trading volume of 395,096 shares, compared to its average volume of 1,534,401. The stock's 50 day moving average is $16.71 and its 200-day moving average is $12.05. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $21.01. The company has a market capitalization of $901.84 million, a PE ratio of -5.89 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. On average, research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Piper Sandler initiated coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an "overweight" rating and a $36.00 price objective on the stock. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. HC Wainwright cut their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim reissued a "buy" rating and issued a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Urogen Pharma presently has an average rating of "Buy" and an average target price of $32.00.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.